[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100557224":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":17,"studyPopulation":21,"armGroups":22,"interventions":32,"overallOfficials":17,"centralContacts":17,"locations":38,"responsibleParty":52,"collaborators":17,"id":56,"slug":17,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":17,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":17,"enrollmentInfo":64,"targetDuration":17,"studyType":67,"phases":17,"briefSummary":68,"conditions":69,"keywords":17,"overallStatus":70,"whyStopped":17,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Far Eastern Memorial Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":17},[9,13],{"measure":10,"description":11,"timeFrame":12},"RFS","Recurrence free survival","the time interval from the date of surgery or the start of chemotherapy to clinically defined recurrence, disease progression, death from any cause or last follow-up",{"measure":14,"description":15,"timeFrame":16},"OS","Overall Survival","the time interval from the date of surgery or the start of chemotherapy to the date of death from any cause or last follow-up",null,{"allocation":17,"interventionModel":17,"interventionModelDescription":17,"primaryPurpose":17,"observationalModel":19,"timePerspective":20,"maskingInfo":17},"CASE_CONTROL","RETROSPECTIVE","woman with recurrent ovarian cancer who was treated with chemotherapy (either intravenous or intraperitoneal)",[23,28],{"label":24,"type":17,"description":25,"interventionNames":26},"intravenous chemotherapy","triweekly chemotherapy with carboplatin AUC=5\\~6 + liposomal-doxorubicin 30\\~40mg\u002Fm2 or paclitaxel 175mg\u002Fm2 0r docetaxel 60\\~75mg\u002Fm2",[27],"Drug: Chemotherapy",{"label":29,"type":17,"description":30,"interventionNames":31},"intraperitoneal chemotherapy","Day 1 IV Paclitaxel 135 mg\u002Fm2 + IP Cisplatin 75-100 mg\u002Fm2 or IP carboplatin (AUC = 6) Day 8 IP Paclitaxel 60 mg\u002Fm2 Every 21 days \\* 6 cycles\n\nOR\n\nDay 1 IP Carboplatin AUC=5 or IP Cisplatin 50-75mg\u002Fm2 Day 2 IV Liposomal doxorubicin 15 mg\u002Fm2 + IP Liposomal doxorubicin 15 mg\u002Fm2 Every 28 days \\* 6 cycles",[27],[33],{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":17},"DRUG","Chemotherapy","Intravenous chemotherapy versus intraperitoneal chemotherapy in recurrent ovarian cancer",[29,24],[39],{"facility":40,"status":17,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":17},"Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital","Banqiao District","New Taipei","22050","Taiwan","TW",{"type":47,"coordinates":48},"Point",[49,50],121.46719,25.01427,{"lat":50,"lon":49},{"type":53,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"PRINCIPAL_INVESTIGATOR","Sheng-Mou Hsiao","Professor","100557224",false,"NCT06535334","Intraperitoneal Chemotherapy in Recurrent Ovarian Cancer","Intravenous Chemotherapy Versus Intraperitoneal Chemotherapy in Recurrent Ovarian Cancer","Inclusion Criteria:\n\n* women who had recurrent ovarian cancer and was treated with either intravenous or intraperitoneal platinum based chemotherapy\n\nExclusion Criteria:\n\n* women who did not complete the designated treatment course (exception to those who had to quit due to progressive disease or death of any cause)","FEMALE","20 Years",{"count":65,"type":66},80,"ESTIMATED","OBSERVATIONAL","This study aims to compare intravenous chemotherapy versus intraperitoneal chemotherapy in patients with recurrent ovarian cancer.",[60],"NOT_YET_RECRUITING","2024-07-31",{"date":73,"type":74},"2024-08-02","ACTUAL",{"date":76,"type":66},"2024-08-15",{"date":78,"type":66},"2026-05",{"name":5,"class":6},1]